Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 2of53 Amendment 3 November 15, 2011PROTOCOL REVIEW AND SIGNATURE FORM
Protocol Title: A Randomized, Double -Blind, Placebo -Controlled
Phase 3 Study to Investigate the Efficacy and Safety of
Progesterone in Patients with Severe Traumatic Brain
Injury
Protocol Number: BHR -100-301
BHR
Pharma, LLC has reviewed the content and format of this protocol and approves Protocol
No. BHR -100- 301 for issuance.
BHR Pharma, LLC Representative
Name (print)
Signature Date
Iagree to conduct the study as detailed herein and in compliance with ICH Guidelines for Good
Clinical Practice and other applicable regulatory requirements, and to inform all who assist me in
the conduct of this study of their responsibilities and obligations.
Principal Investigator
Name (print)
Signature Date
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 4of53 Amendment 3 November 15, 2011Thesubjects willbemanaged inaccordance with thestandard guidelines
forthemanagement ofsevere TBI: BTF, ABIC, andEBIC (BTF, 2007;
ABIC, 2003; Maas et
al.,1997, respectivel y).
Anindependent DSMB will beappointed tohave responsib
ilityfor
safeguarding theinterests oftrial subjects, andassessing thesafet yand
efficacy of the study treatments during the trial.
Treatment allocation will bedone using acentralized randomization
system.
Number of
SubjectsThe planned total number of subjects will be 1180, randomized equally to
BHR -100 or placebo.
Diagnosis and
Main Criteria for
Inclusion1.Male orfemale patients, agebetween 16and70years,inclusive (or
other age limits as required by local regulations)
2. Weight from 45 to 135 kg, inclusive
3.Sustained a closed head trauma no more than 8 hours before initiation
ofstudy druginfusion ( exposed dura mater isacceptable inthecase
of depressed skull fractures)
4.TBI diagnosed b y history and clinical examination
5. GCS score between 3 and 8, inclusive
6. At least one reactive pupil (pinpoint pupils due toopioid pain
treatment are considered r eactive)
7.Evidence ofTBI confirmed byabnormalities consistent with trauma
on CT scan upon admission (Diffuse injury II-IV,evacuated andnon-
evacuated
mass lesion, Mars hall’s CT Classification)
8. Indication for ICP monitoring
Exclusion Criteria 1.Life expectancy ofless than 24hours asdetermined bythe
Investigator
2.Prolonged and/or uncorrectable hypoxia (Pa02< 60mmHg) or
hypotension (systolic blood pressure <90mmHg) atthetime of
randomization
3.Any spinal cord injury
4.Pregnancy
5.Penetrating he ad injury
6.Bilaterally fixed dilated pupils at the time of randomization/
7.Coma suspected to be primarily due to other causes (e.g. alcohol)
8. Pure epidural hematoma
9. Preexisting clinically significant disease orchronic condition thatcan
beascertained atthetime ofadmission andcould affect functional
outcome
10.Severe cardiac or hemodynamic instability prior to randomization
11.Known treatment with another investigational drug, device, medical
therap y or procedure within 30 days of injury
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 6of53 Amendment 3 November 15, 2011ventricular drainage
hyperosmolar therapy
blood pressure supportive agents
hyperventilation
barbiturates
surgical decompression for refractory ICP control
Primary Efficacy
AnalysisThe primary efficacy variable is GOS evaluated at 6 months post injury .
The proportional odds model (POM) (McCullagh, 1980) willbeused to
compare BHR -100 toplacebo fortheGOS outcome atsixmonths
(categories ofgood recovery ,moderate disabi lity, severe disability ,and
thecombined vegetative state/death). A testfortheproportional odds
assumption will beconducted and ifstatistically significant, other
polytomous logistic models will beinvestigated
.The analy seswill be
conducted onanintent -to-treat (ITT) basis ,andthePOM will befitted
including theeffect oftreatment, geographic region (North America,
Europe, Asia, and South America), age, GCS motor score, pupil
response, and CT classification.
Ifthep-value from the test ofthenull hypothesis islessthan 0.0003 (at
theinterim analy sis) or 0.0098 (at the final analy sis), it will be concluded
that BHR -100 isstatistically significantly different from placebo with
respect
to the GOS at 6 months following injury .
Sample Size
JustificationAtotal sample size of1180 patients i splanned; patients w illbe
randomized ina1:1ratio toBHR -100 orplacebo. Thissample size
estimate was determined using aproportional odds model (Whitehead,
1993) of the 6- month
GOS outcome distrib ution from the population with
baseline GCS 3-8 inprevious TBI Phase 3 trials intheIMPACT
Database (Marmarou etal.,2007). Randomization will bestratified by
major geographical regions ofthesite locations in order tomaintain
overall equivalent tre atment group size.
Baseline Data
AnalysisBaseline comparability ofthetreatment groups for themost important
prognostic factors (age, GCS motor score atbaseline, pupillary response
and CTclassification) will beillustrated using appropriate descript ive
statistics.
Safety
Monitoring/DSMBAn independent DSMB will review safet yand efficacy data from the trial
inablinded fashion. Thedata willbeprovided totheDSMB statistician
atapproximately 100-subject intervals, with precise intervals tobe
determined inconsultation with theDSMB. TheDSMB will determine
the ty pe of data and statistical comparisons required for review.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 7of53 Amendment 3 November 15, 2011Interim Analysis Aformal interim analy sisonthe6-month GOS will beperformed once
thefirst 200subjects ineach arm(400 total)
have been assessed. Atthe
planned interim analy sis,atwo-sided testwill beconducted todetect
either
an increase or decrease in the common odds ratio.
Any consideration toprematurely discontinue thetrial will bediscussed
bythe study statistician with the DSMB and the sponsor. In order to stop
thetrial ataninterim analysisbecause offavorable outcome, the
significance level will need to be less than the critical p -value of 0.0003.
Safety Analysis AllAEs andSAEs will besummarized bycounts ofsubjects with AEs
and individual occurrences according to the MedDRA coding.
The following will besummarized both astheobserved values and,
where applicable, the changes from baseline of the va lues:
Vital signs
Safety labs
ECG variables
AEsummaries will include abnormal, clinicall ysignificant labresults
deemed b y the Investigator as AEs.
Counts and percentages of subjects with each symptom of
neuroworsening will be described.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 8of53 Amendment 3 November 15, 2011TABLE OF CONTENTS
Page
STUDY SYNOPSI S ................................................................................................................. 3
LIST
OF TABLES .................................................................................................................. 10
LIST
OF ABBREVIATIONS AND TERMS......................................................................... 10
1.INTRO DUCTION
AND RATIONALE .......................................................................... 13
1.1 Background ................................
............................................................................................ 13
1.2 Progesterone as a Neuroprotectant: Pre–Clinical Studies ...................................................... 13
1.3 Progesterone as a Neuroprotectant: Clinical Studies in TBI .................................................. 14
1.4 Rationale for Timing of Drug Administration ....................................................................... 15
2.STUDY OBJECTIVES .................................................................................................... 16
2.1 Primary
Objective .................................................................................................................. 16
2.2 Secondary Objectives ............................................................................................................. 16
3.STUDY DESIGN ................................ ................................ ................................ ............. 17
3.1 Description of Overall Study Design ..................................................................................... 17
3.2 Study Endpoints ..................................................................................................................... 17
3.2.1 Primary Endpoint ............................................................................................................. 17
3.2.2 Secondary Endpoints ....................................................................................................... 17
4.SELECTION OF STUDY POPUL ATION ..................................................................... 19
4.1 Inclusion
Criteria .................................................................................................................... 19
4.2 Exclusion Criteria ................................................................................................................... 19
4.3 Withdrawal of Subjects from the Study ................................................................................. 20
4.3.1 Subject Replacement ....................................................................................................... 20
5.STUDY MEDICATION .................................................................................................. 21
5.1 Blinding
and Unblinding ........................................................................................................ 21
5.2 Formulation, Packaging, and Labeling ................................................................................... 21
5.3 Storage .................................................................................................................................... 21
5.4 Dispensing.............................................................................................................................. 21
5.5 Dosage and Administrati on.................................................................................................... 22
5.6 Drug Accountability ............................................................................................................... 22
5.7 Assessment of Compliance .................................................................................................... 22
5.8 Concomitant Medications ...................................................................................................... 22
5.8.1 Allowed Concomitant Medications/Procedures .............................................................. 22
5.8.2 Concomitant Medications/Therapies to be Avoided ....................................................... 22
6.
STUDY PROCEDURES ................................ ................................ ................................ . 23
6.1 Screening ................................................................................................................................ 23
6.2 Screening and Randomization Process (IWRS) ..................................................................... 24
6.3 Study Drug Infusion Period: Days 1-5................................................................................... 24
6.4 Day 6: End-of- Infusion Evaluations ....................................................................................... 25
6.5 Day 15: Post -Infusion Evaluations/Discharge ....................................................................... 25
6.6 Day 30 (Month 1) Assessments ............................................................................................. 26
6.7 Day 90 (Month 3) Assessments ............................................................................................. 26
6.8 Day 180 (Month 6) Assessments ........................................................................................... 26
6.9 Progesterone Blood Sample Collection .................................................................................. 26
7.ASSESSMENTS OF EFFICACY AND SAFETY .......................................................... 27
7.1 Efficacy
Parameters ................................................................................................................ 27
7.2 Safety Parameters ................................................................................................................... 27
7.2.1 Adverse Events and Serious Adverse Events .................................................................. 27
7.2.2 ECG ................................................................................................................................. 27
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 9of53 Amendment 3 November 15, 20117.2.3 Laboratory Safety Tests ................................................................................................... 28
7.2.4 Vital Signs ....................................................................................................................... 28
7.2.5 Daily Fluid Balance ......................................................................................................... 28
7.2.6 Arterial Blood Gases ....................................................................................................... 28
7.2.7 Neuroworsening ............................................................................................................... 28
7.3 Selection of Efficacy Measurements Related To Management of TBI .................................. 28
7.3.1 Glasgow Outcome Scale (GOS) ...................................................................................... 28
7.3.2 Glasgow Outcome Scale - Extended (GOS- E)................................................................ 28
7.3.3 Mortality .......................................................................................................................... 29
7.3.4 Intracranial Pressure/Cerebral Perfusion Pressure ........................................................... 29
7.3.5 Therapeutic Intensity Level (TIL) ................................................................................... 29
7.3.6 CT Scans .......................................................................................................................... 30
7.3.7 QOL SF -36 ...................................................................................................................... 30
7.3.8 Glasgow Coma Scale ....................................................................................................... 30
8.STATI STICAL PLAN ..................................................................................................... 31
8.1 Sample
Size Justification ....................................................................................................... 31
8.2 Baseline Data ......................................................................................................................... 31
8.3 Primary Efficacy Analysis ..................................................................................................... 31
8.3.1 Alternate Primary Efficacy Analysis: Sliding Dichotomy Model .................................. 31
8.3.2 Sensitivity Analysis: Dichotomized Model .................................................................... 32
8.3.3 Handling of Missing Primary Efficacy Endpoint Data .................................................... 32
8.4 Secondary Endpoints and Exploratory Endpoints .................................................................. 33
8.4.1 Mortality Assessment at One and Six Months Post -injury .............................................. 33
8.4.2 Secondary Analyses of GOS at Three Months Post -injury ............................................. 33
8.4.3 GOS -E at Three and Six Months Post -injury .................................................................. 33
8.4.4 Quality of Life using SF -36............................................................................................. 34
8.4.5 Exploratory Clinical Parameters: ICP, CPP and TIL ...................................................... 34
8.4.6 Exploratory Parameter: CT Scan .................................................................................... 34
8.5 Adverse Event Safety Data .................................................................................................... 35
8.6 Interim Analysis ..................................................................................................................... 35
8.6.2 Futility Analysis .............................................................................................................. 35
9.ADVERSE EVENT COL LECTION AND REPORTI NG.............................................. 37
9.1 Adverse
Event Collection ....................................................................................................... 37
9.2 Reporting of Adverse Events ................................................................................................. 37
9.3 Assessment of Adverse Event Severity .................................................................................. 38
9.4 Serious Adverse Events and Expedited Reporting ................................................................. 39
9.5 Notification of Sponsor .......................................................................................................... 40
9.6 Procedures f or Reporting Pregnancy Exposure and Birth Events .......................................... 41
10. REGULATORY AND PROCEDURAL REQUI REMENTS ....................................... 42
10.1 Ethical
Conduct of the Study................................................................................................ 42
10.2 Independent Ethics Committee or Institutional Review Board ............................................ 42
10.3 Subject Information and Consent ......................................................................................... 42
10.4 Data Safety Monitoring Board ............................................................................................. 43
10.5 Steering Committee .............................................................................................................. 43
10.6 ABIC (American Brain Injury Consortium) ........................................................................ 44
10.7 Investigator Obligations ....................................................................................................... 44
10.8 Electronic Case Report Forms (eCRFs) ............................................................................... 44
10.9 Monitoring the Study ........................................................................................................... 44
10.10 Protocol Deviations ............................................................................................................ 44
11. DATA HANDLING AND RECORDKEEPI NG.......................................................... 45
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 10of53 Amendment 3 November 15, 201111.1 Disclosure of Data ................................................................................................................ 45
11.2 Publication ............................................................................................................................ 45
11.3 Record keeping and Retention ............................................................................................. 45
12. REFERENCES .............................................................................................................. 46
APPENDIX
A SCHEDULE OF EVENTS ............................................................................. 51
APPENDIX
B LABORATORY ASSESSMENTS (Screening, Day 6, Day 15).................. 52
LIST OF TABLES
Page
Table 1 Therapeutic Intensity Level Grading Sy stem ............................................................ 29
Table
2 Critical Values and p- Values for Planned Interim Anal ysis...................................... 35
Table
3 Futility Anal ysis: Power to Reject Null Hy pothesis under Various Scenarios .......... 36
LIST OF ABBREVIATION S AND TERMS
ABIC American Brain Injury Consortium
ABG Arterial Blood Gases
AE Adverse Event
BTF Brain Trauma Foundation
CPP Cerebral Perfusion Pressure
CRF Case Report Form (paper or other media)
CT Computed Tomograph y
DRS Disability Rating Scale
DSMB Data Safet y Monitoring Board
EBIC European Brain Injury Consortium
ECG Electrocardiogram
EU European Union
FDA Food and Drug Administration
GCP Good Clinical Practice
GCS Glasgow Coma Scale
GMP Good Manufacturing Practice
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 11of53 Amendment 3 November 15, 2011GOS Glasgow Outcome Scale
GOS -E Glasgow Outcome Scale -Extended
HCO 3 Bicarbonate (in ABG)
ICH International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use
ICP Intracranial Pressure
ICU Intensive Care Unit
IEC Independent Ethics Committee
i.m. intramuscular
IMPACT International Mission fo r Prognosis and Analy sis of Clinical Trials in TBI
IND Investigational New Drug
IRB Institutional Review Board
ITT Intent -to-treat
i.v. intravenous
IWRS Interactive Web Response Sy stem
KPS Karnofsk y Performance Scale
LOCF Last Observation Carried Forward
LAR Legally Authorized Representative [per U.S. F.D.A. regulations 45 CFR
46.102(c) and 21 CFR 50.3(l)] and
Legally Acceptable Representative [per ICH E6 CPMP/I CH/135/95]
MedDRA Medical Dictionary for Regulatory Activiti es
NDA New Drug Application
PIP Progressive Intracranial Pathology
PaCO 2 Carbon Dioxide (in ABG)
PaO 2 Partial Pressure of Ox ygen (in ABG)
POM Proportional Odds Model
ProTECTTMProgesterone for Acute Traumatic Brain Injury Trial Experimental Clinical
Treatment
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 12of53 Amendment 3 November 15, 2011QOL Quality of Life
SAE Serious Adverse Event
SaO 2 Arterial Ox ygen Saturation (in ABG)
SAP Statistical Analy sis Plan
SD Standard Deviation
SF-36 Short Form (36) Health Survey
TBI Traumatic Brain Injury
TIL Therapeutic Intensit yLevel
TNF Tumor Necrosis Factor
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 13of53 Amendment 3 November 15, 20111. INTRODUCTION AND RAT IONALE
1.1 Background
Traumatic Brain Injury (TBI) is a leading cause of death and disability worldwide. In Europe, an
overall average TBI incidence ratederived from estimates ofhospitalized patients plus deaths is
about 235 per100,000 (Tagliaferri etal.,2006) and inChina, severe TBI accounts for
approximately 20% of brain injuries (Wu et al., 2008).
The U.S. Centers for Disease Control and
Prevention (CDC) estimate that more than 1.7million Americans sustain TBI each year. Of
these, approximately 1.36 million require emergency department visits, 275,000 are hospitalized,
and52,000 die(Faul etal.,2010). IntheU.S. children aged 0to4years, older adolescents aged
15
to 19 y ears, and adults aged 65 years and older are the age groups most likely to sustain a TBI
(Faul et al., 2010)
TBI isgraded asmild, moderate, orsevere onthebasis oftheGlasgow Coma Scale (GCS).
Insevere injury (GCS 3-8)thesubject iscomatose, unable toopen their eyes or follow
commands (Teasdale and Jennett, 1974). Severe TBI accounts for more than 57,000 hospitalized
patients in theU.S. each year, andmortality rates arehighest inthesevere category ofTBI.
Studies involving about 6000 severe TBI patients (GCS ≤8)observed mortality rates ranging
from 20% toashigh as39%, translating into perhaps 11,000 – 22,000 deaths peryearinthis
population (Marmarou etal.,2007
).According totheCDC, 5.3million Americans (2%ofthe
population) are living with some degree ofdisability from aprior TBI (Brown etal.2008; CDC,
2008). These patients have along-term orlifelong need forhelp toperform activities ofdaily
living asaresult ofTBI. IntheUS, thedirect andindirect costs ofTBI areestimated at$60
billion (L anglois et al., 2006).
1.2 Progesterone
as a Neuroprotectant: Pre –Clinical Studies
Progesterone, primarily known asagonadal hormone, isanimportant agent affecting many
functions inthecentral nervous system, where itisalso locally synthesized, anditmay playan
important roleinpromoting andenhancing repair after traumatic brain injury andstroke (Stein,
2005
). A s ystematic review ofexperimental studies indicates that progesterone is
neuroprotective, interms ofreducing
lesion volume, following either cerebral ischemia or
traumatic brain injury (Gibson etal.,2008). Progesterone also hasbeen shown toreduce post-
injury edema inrats(Roof etal.,1993) aswell asimprove cognitive recovery andsecondary
neuronal loss caused bycontusion injury (Roof etal.,1994). The protection against post-
traumatic edema was seen inanimals tr eated upto24hours post injury (Roof etal.,1996).
Progesterone also hasbeen shown toprotect against lipid peroxidation following TBI inrats
(Roof
et al., 1997).
Progesterone hasamembrane stabilizing effect thatserves toreduce thedamage caused bylipid
peroxidation. Inaddition, itmay provide neuroprotection bysuppressing neuronal
hyperexcitability (Sayeed etal.,2007). Experimental studies byseveral investigators have
documented theneuroprotective effects ofprogesterone invarious models oftraumatic brain
injury and stroke (Cutler et al., 2007; Cutler et al.,2005; Cutler et al., 2006; Djebaili et al., 2005;
Djebaili etal.,2004; Duvdevani etal.,1995; Galani etal.,2001; Grossman etal.,2004; Guo et
al.,2006; Heetal.,2004; Pettus etal.,2005; Roof etal.,1994; Roof etal.,1996; Roof etal.,
2000;
Sayeedet al.,2007; Shear et al., 2002; VanLandingham et al., 2007; Wright et al., 2001).
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 14of53 Amendment 3 November 15, 20111.3 Progesterone as a Neuroprotectant: Clinical Studies in TBI
Based upon alarge and growing body ofpreclinical evidence demonstrating thepowerful
neuropro tective properties ofprogesterone ,thefeasibility ofprogesterone therap ywasstudied to
assess itsapplicability inpatients with acute TBI. One pilot study (Xiao etal.,2007) andtwo
Phase 2 trials (Wright etal.,2007; Xiao etal.,2008
)have been conducted with parenterally -
administered progesterone, and theresults have revealed anacceptable safety profile and
promising efficacy outcomes to support further studies.
APhase 2 randomized, double blind, placebo
-controlled trial (the Progesterone forAcute
Traumatic Brain Injury Trial Experimental Clinical Treatment (ProTECT ™) study )was
conducted byWright etal.(2007) in100adult TBI patients
arriving within 11hours ofinjury
andwith a pre -resuscitation GCS ranging from 4 to 12. Patients were randomized on a 4:1 basis
toreceive either intravenous (i.v.) progesterone orplacebo. Subjects were assessed dailyfor
adver seevents andsigns ofrecovery .Safetyandefficacy outcomes were assessed at30days
post-injury .Theprimary safetymeasures were adverse event rates andmortality .Theprimary
measure of benefit was the dichotomized Glasgow Outcome Scale Extended (G OS-E).
IntheProTECT ™study (Wright etal.,2007), 77subjects were randomized toprogesterone and
23toplacebo. Themean time from injury toinitiation ofprogesterone/placebo infusion was6.3
hours. A progesterone alcohol solution was mixed with Intralipid®20% (Fresenius Kabi,
Clay ton,NC),andthemixture infused ataninitial rateof14mL/hr(0.71 mg/kg/h) for1hour
followed bya decrease ininfusion rateto10mL/h r(0.5mg/kg/h r)foroverall treatment duration
of72hours .Subjects treated with placebo received thesame infusion regimen minus the
progesterone. The treatment groups had similar baseline demographic and clinical
characteristics. Laboratory and phy siologic values were similar throughout treatment.
Noserious adverse events were attributed toprogesterone. Adverse andserious adverse event
rates were similar inboth groups, except that subjects treated with progesterone hadalower 30-
daymortality ratethan those intheplacebo group (Relative Risk[RR] 0.43; 95% confidence
interval 0.18 to0.99). Themajority ofsevere (GCS 4-8)TBI survivors inboth groups had
relativel ypoor
GOS -E and Disability Rating Scale (DRS) scores. However, moderate TBI (GCS
9-12) survivors who received progesterone were more likely tohave amoderat e -to-good
outcome than those randomized toplacebo. Itwas concluded that, inthis small study ,
progesterone caused no discernible harm and showed possible signs of benefit.
Thepharmacokinetics ofprogesterone intravenous infusion were examined intheabovetrial in
33subjects (Wright etal.,2005). Multiple blood samples were obtained from 11female and21
male subjects receiving progesterone infusions and 1female and 3males receiving placebo
infusions for72hours. Analysesdemonstrated that stable progesterone concentrations canbe
rapidly achieved via progesterone infusion following TBI.
Inapilot randomized trial (Xiao etal.,2007), thetherapeutic effects ofintramuscular (i.m.)
progesterone were studied in56TBI patients with baseline GCS of5 to
8.Twent ysixwere
treated with progesterone and30subjects received placebo. Neurologic outcome was assessed
using theGlasgow Outcome Scale (GOS) and theKarnofsk yPerformance Scale (KPS). Three-
month follow upindicated thatGOS, KPS, andthedegree ofverbal impairment were better in
theprogesterone -treated group than inthecontrol group (p< 0.05); however there was no
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 15of53 Amendment 3 November 15, 2011significant difference in mortality . Serum 15 -F(2t) -isoprostane and tumor necrosis factor (TNF) -
alpha levels were reduced significantl yintheprogesterone- treated group onthe5thand 10thday
after injury (p<0.05), supporting thenotion thatthepositive effects ofprogesterone may bedue
to its alleviating inflammatory and lipid peroxidation response .
Following theabove study ,Xiao etal.conducted aprospective, randomized, placebo- controlled
trial ofprogesterone in159severe TBI patients with aGCS 3-8who arrived within 8hours of
injury (Xiao etal., 2008
).Patients w ererandomized toreceive intramuscular lyeither
progesterone (n=82)orplacebo (n=77). At3months and6months after treatment, subjects
given progesterone had significantly more favorable functional outcomes and decreased
mortality compared with placebo-
treated subjects (mortalit y at 6 months p< 0.05).
Insummary ,studies have shown thatadministering relativel ylarge doses ofprogesterone during
thefirst few hours todaysafter injury significantly limits central nervous system damage,
reduces loss of neural tissue, and improve s functional recovery . Although the research published
todate hasfocused primarily onprogesterone's effects onblunt TBI, there isevidence thatthe
hormone affords protection from several forms ofacute central nervous system injury ,including
penetra ting brain trauma, stroke, anoxic brain injury ,and spinal cord injury .Progesterone
appears toexert itsprotective effects byprotecting orrestoring theblood -brain barrier,
attenuating cerebral edema, down -regulating theinflammatory cascade, and limiting cellular
necrosis and apoptosis. All are plausible mechanisms of neuroprotection (Stein, 2008).
1.4 Rationale
for Tim ing of Drug Administration
The start ofinfusion inthis clinical trial must occur within 8hours ofthetime ofinjury ,
preferabl yassoon aspossible, inaccordance with the“Golden Hour” principle ofemergency
medicine thatearlier treatment isbetter. Whileoneanimal model ofTBI suggests progesterone
hasatherapeutic window thatcontinues outto24hours post-injury (Roof etal.,1996 ),efficacy
seemed todiminish asafunction oftime prior totreatme nt. Moreover, thepresumed
mechanisms ofaction forprogesterone inTBI argue forearlier intervention. While
progesterone has many pro-trophic effects that affect damage repair andcould be responsible for
the large observed treatment window, an ideal neuroprotective agent should prevent damage ,and
the
pathogenesis of TBI begins very earlypost-injury .
Although themechanistic and preclinical considerations drive earlier treatment, there are
practical obstacles ofinformed consent andstudy treatment preparation thatmust beconsidered.
Patients areunable toprovide consent duetolevel ofconsciousness, therefore consent must be
sought from arelative orother authorized representative ,aspermitted bylocal regulations.
Feasibility research indicates that obtaining informed consent will berate-limiting andif,for
example, only 6 hoursare allowed fortreatment initiation, timely enrollment becomes
problematic. The8-hour window required inthis protocol strikes theappropriate balance
between theneed forearly initiation oftreatment and therequirement toobtain appropriate
inform ed
consent.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 16of53 Amendment 3 November 15, 20112. STUDY OBJECTIVES
2.1 Prim ary Objective
The aimofthestudy istodetermine theefficacy andsafet yofBHR -100 utilizing the6-month
GOS in severe TBI patients (GCS 3-8)following 120 hour s of st udytreatment.
2.2 Secondary Objectives
Inaddition, theclinical benefit ofprogesterone treatment will befurther assessed through the
evaluation of:
1.mortality at 1 month and 6 months post injury
2.GOS at 3 months
3.GOS -E at 3 and 6 months
4.Quality of Life using Short Form (36) Health Survey (SF-36) at 3 and 6 months
5.theeffect onIntracranial Pressure (ICP), Cerebral Perfusion Pressure (CPP), and
Therapeutic Intensit yLevel (TIL)
6.theeffect ontheprogression ofintracranial pathology asassessed bytheadmission
and the Day 6 (+/ -1 Day) computed tomograph y (CT) scans
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 17of53 Amendment 3 November 15, 20113. STUDY DESIGN
3.1 Description of Overall Study Design
This isamulti -center, randomized ,double blind, placebo controlled study conducted on 1180
severe TBI patients a t100 ormore international trauma centers (sites). Allsubjects will be
managed inaccordance with standard guidelines for TBI from theBrain Trauma Founda tion
(BTF), American Brain Injury Consortium (ABIC) and European Brain Injury Consortium
(EBIC) (BTF, 2007; ABIC, 2003; Maas et al., 1997).
Randomization will beimplemented using Interactive Web -based Response System (IWRS)
technology .Randomization willbestratified bymajor geographical regions. The post-
stabilization GCS of3to8,assessed atthestudy center, willserve astheindex (randomization)
GCS. Ifatrue index GCS atarrival isnotfeasible duetomedically indicated measures (i.e.,
GCS is3due tosedation and paral ysis),theInvestigator needs toobtain areliable GCS
assessment obtained bytheEmergency Team atthescene ofinjury (field GCS) and/or other
transferring medical facility .Thescore must include each component ofthescore(eyeopening,
verbal andmotor responses), and must total 3 -8.Any reliable GCS of 3 to 8, inclusive, qualifies
thepatient forstudy enrollment. Tomaintain theblind, all study procedures are to be performed
bysite personnel blind to treatment assig nment.
Subjects will beintensively monitored during thefive-dayinfusion period andtheir Intensive
Care Unit (ICU) stay.Thestart andduration ofICP monitoring will beatthediscretion ofthe
sitebased onthe subject’s clinical condition. IftheICPmonitor isplaced, ICPandTILwill be
recorded foraperiod ofuptosixdays.Thebaseline CTscanused forrandomization anda
second CTscan obtained onDay 6 (+/-1 day)will becentrally analyzed forprogressive
intracranial pathology (PIP).
Adverse events (AEs) willbecollected beginning atthestart ofstudy druginfusion andthrough
Day 10post-infusion (Day s1-15). Serious adverse events (SAEs) willbecollected beginning at
thestart ofstudy druginfusion, continuing throughout thesix-mont hsubject duration inthe
study .
The
GOS will be collected at three and six months as well as the GOS -E.
The Schedule of Events is shown inAppendix A .
3.2 Study Endpoints
3.2.1 Prim ary Endpoint
GOS evaluated at Month 6 post- injury .
3.2.2 Secondary Endpoints
Secondary endpoints will be assessed by the following measures:
Mortality assessment at 1 month and 6 months post TBI
Evaluation of GOS at 3 months
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 18of53 Amendment 3 November 15, 2011Evaluation of the GOS -E at Months 3 and 6
SF-36 at Months 3 and 6
Changes in ICP, CPP ,and TIL
Changes
inintracranial pathology as assessed b y the admission and end -infusion Day 6
(+/-1 Day ) CT scans.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 19of53 Amendment 3 November 15, 20114. SELECTION OF STUDY P OPULATION
One thousand onehundred andeight ysubjects (1180) willbeenrolled inthistrial. Patients who
have severe TBI and who meet the following inclusion/exclusion criteria will be eligible.
4.1 Inclusion Criteria
1.Male orfemale pa tients, agebetween 16and70years,inclusive (or other agelimit as
required b y local regulations)
2. Weight from 45 to 135 kg, inclusive
3.Sustained aclosed head trauma nomore than 8hours before initiation ofstudy drug
infusion (exposed dura mater is acceptable in the case of depressed skull fractures)
4.TBI diagnosed b y history and cli nical examination
5. GCS score between 3 and 8, inclusive
6. At least onereactive pupil (pinpoint pupils duetoopioid pain treatment areconsidered
reactive)
7.Evidence ofTBI confirmed byabnormalities consistent with trauma onCTscan upon
admission (diffuse injury II-IV,evacuated and non -evacuated mass lesion, Marshall’s CT
Classification)
8. Indication for ICP monitoring
4.2 Exclusion Criteria
1.Life expectancy ofless than 24 hours as determined by the Investigator
2.Prolonged and/or uncorrectable h ypoxia (Pa02< 60mmHg) orhypotension (systolic
blood pressure < 90 mmHg) at the time of randomization
3.Any spinal cord injury
4.Pregnancy
5.Patients with penetrating head injury
6.Bilaterally fixed dilated pupils at the time of randomization
7.Coma suspected to be primarily due to other causes (e.g. alcohol)
8. Pure epidural hematoma
9. Preexisting clinicall ysignificant disease orchronic condition thatcanbeascertained at
the time of admission and could affect functional outcome
10.Severe cardiac or hemodynamic instability prior to randomization
11.Known treatment with another investigational drug, device, medical therapy or procedure
within 30 day s of injury
12.Ahistory ofallergic reaction toprogesterone andrelated drugs oranyofthecomponents
of the infusion
13.Any disease, in the opinion of the Investigator, that is unstable orwhich could jeopardize
the safet y of the patient and his/her compliance in the study.
14.Patients who, intheopinion oftheInvestigator, would notbeable orwilling tocomply
with the protocol through the final visit (6 months post- injury )
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 20of53 Amendment 3 November 15, 20114.3 Withdrawal of Subjects from the Study
Agood faith effort willbemadetoensure thatsubjects complete thestudy through the6-month
assessments, consistent with
the provisions of informed consent andgood clinical judgment with
respect tosafety. Thefollowing arepotential reasons toterminate theparticipation ofasubject
in the study :
The subject’s health would be jeopardized by continued partic ipation.
Lost to follow -up: subject fails to return to the study site for scheduled visits and does not
respond tomultiple telephone orwritten attempts tocontact .(Note: ifsubject cannot
return tothestudy siteduetorelocation, butmoves toanarea nearanother participating
site, all efforts should be made to continue study participation at that site).
Withdrawal ofconsent: subject orthesubject’s legall yauthorized representative or
legally acceptable representative (LAR), asapplicable intheregion where thestudy is
conducted, decides tostop participation inthestudy foranyreason other than anAE, or
isunable tocomplete thestudy asdescribed inthestudy protocol .Although asubject or
LAR isnotobliged togivehis/her reason forwithdrawing prematurel y,theInvestigator
will make areasonable effort toobtain thereason while fullyrespecting thesubject’s
rights .Every effort will bemade tocontact asubject orLAR who fails toattend any
follow -up appointments/contacts in order to complete study assessments.
Administrative: theSponsor decides toterminate ordiscontinue the study (either atthe
study site or the entire study ).
The reason forwithdrawal will becaptured ontheappropriate elect ronic case report form
(eCRF ).TheStudy Termination form must becompleted forallrandomized subjects, including
subjects discontinuing priortoanystudy drugadministration. The Medical Monitor will be
informed of earl y withdrawal of a subject from the study .
4.3.1 Subject Replacement
Subjects who do not complete the study for any reason will not be replaced.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 22of53 Amendment 3 November 15, 20115.5 Dosage and Administration
Subjects willbeadministered either BHR -100 orplacebo infusion utilizing aperistaltic infusion
pump . An i.v.loading dose ofBHR -100 orplacebo forthefirst hour at0.71 mg/kg/hr will be
followed bya 119-hrcontinuous maintenance infusion of0.5mg/kg/hr, foratotal of120hours
oftreatment. TheIWRS calculates theloading andmaintenance infusion rates according tothe
subject’s weight enteredinto theIWRS. The rates assigned forthesubject (loading dose,
followed b y maintenance infusion) must be used to administer the study drug.
Study druginfusion treatment must bestarted within 8hours afterinjury using adedicated i.v.
line (central or peripheral line).
5.6 Drug Accountability
The Investigator will maintain accurate records ofthedisposition ofallclinical drug supplies
received during thestudy andthedates onwhich drug supplies were received from theSponsor
or authorized representative.
5.7 Assessment of Com pliance
Study drugwill beadministered byqualified clinical personnel. Attheendofthestudy drug
administration aclinical research staff member will verifythattheentire dose (120 total hours
from start tofinish) hasbeen administered tothesubject. Alldetails of thestudy druginfusion
will berecorded, including anyinterruption andthereason. Anydoseinterruptions greater (>)
than 30 minutes will be recorded as a protocol deviation.
5.8 Concom itant Medications
Allother medications administered toortaken bythesubject during thestudy (from time of
consent through Study Day 15)areto be recorded on the eCRF. Informati on should be recorded
for:name ofdrug, dose, route ofadministration, start and end dates and time (fori.v. drugs), and
indication, including medications used for ICP management.
5.8.1 Allowed Concom itant Medications/Procedures
Allmedications andprocedures required totreat the subject’s TBI should beadministered as
recommended inthestandard guidelines for themanagement ofsevere TBI (BTF, ABIC,and
EBIC) . Any therapeutic or surgical procedure performed for concurrent condition s from the time
ofinformed consent through Study Day15 should be recorded, including thedate, description of
theprocedure, andclinical findings. Thenature andvolume ofi.v.fluids willbemeasured ona
daily basis and any other fluid/blood/blood pr oduct replacement will be documented.
5.8.2 Concom itant Medications/Therapies to be Avoided
Investigational drugs, devices, procedures ortherapies should notbeused atanytimeduring the
subject’s 6-month participation inthestudy because oftheir potential toconfound theresults.
Subjects participating inthisclinical trial should not alsobeenrolled inanother trial utilizing
anyinvestigational drug, device, procedure ortherapy .Enrollment into astrictly observational
trial
is permitted, as long as the study assessments in this trial are not compromised.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 23of53 Amendment 3 November 15, 20116. STUDY PROCEDURES
The Schedule ofEvents (Appendix A)summarizes thefrequency andtiming oftherequired
study assessments.
The subject should bemanaged forTBI asrecommended intheBTF, ABIC,and EBIC
guidelines for the management of severe TBI.
Inorder nottointerfere with thestandard ofmedical careandtominimize additional study -
specific procedures, some ofthesubject’s baseline characteristics will berecorded from
procedures performed routinely forthemanagement ofsevere TBI.Except where otherwise
specified below, thelastavailable values priortostudy randomization willberecorded .These
may include general (physical andneurological) examination findings. These data may evenbe
obtained in another hospital , and are acceptable to record in the eCRF.
6.1 Screening
The following assessments will be conducted after arrival of the patient atthe study hospital.
Demographic
data
Review of inclusion/exclusion criteria
Review of relevant medical history
Review of medication history
Informed Cons ent
Full phy sical examination including:
Body weight
Right and left pupil response must be recorded
Injury Cause and Severity Assessment
Vital signs
Obtain blood samples for local lab assessments (see Appendix B for details)
Serum or urine pregnancy test for women of child -bearing potential
ECG
GCS (all components: Eye opening, Verbal Response, and Motor Response)
Baseline CT scan
If the ICP monitor is placed , monitoring of:
ICP
TIL
Arterial Blood Gases (ABG): While the subject is intubated, the highest value of the day
forthePaCO 2and the lowest value of the day for PaO 2, pH, HCO 3and SaO 2, along with
the accompan ying Fio 2setting, will be recorded.
Concomitant medications/procedures
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 24of53 Amendment 3 November 15, 20116.2 Scre ening and Rando mization Process (IWRS)
Subjects will berandomized toeither placebo oractive drug ona1:1ratio. Randomization is
stratified byregion (North America, South America, Europe, and Asia). Onceasubject is
determined eligible forthestudy andinformed consent hasbeen obtained, theInvestigator or
designee willaccess theweb-based randomization system (IWRS), andwill reply tothesystem
questions asprompted. Allsubjects (orthe
subject’s LAR) from whom informed consent is
obtained should be entered into I WRS. Screening information will be entered into the I WRS for
the screened subj ect:
Date and time of injury , date and time of informed consent, date of birth
GCS
Subject initials, gender, and weight
TheIWRSwillassign theSubject identification (ID) number. Thisassigned IDnumber willbe
used throughout the subject’s participat ion in the study .
All screening procedures should be completed and inclusion/exclusion criteria confirmed prior to
therandomization intheIWRS. Oncethesubject isreadytoberandomized intothestudy ,the
Investigator ordesignee will loginto IWRS, s elect thescreened subject number andconfirm
inclusion/exclusion criteria. Upon confirmation, IWRS will provide aRandomization
Notification including the following information:
Assigned bottle numbers for the five day infusion;
The loading dose infusio n rate in milliliters per hour for the first hour;
Themaintenance dose infusion rateinmilliliters perhour fortheremaining 119hours of
administration.
Careful attention should bepaid to correctly administering theassigned study drug as well
asadmi nistering theassigned loading and maintenance dose infusion rates asthese are
calculated according to the subject’s weight (see Section 5.5).
6.3 Study Drug Infusion Period: Days 1 -5
The study treatment infusion MUST beinitiated nolater than 8hours after the
documented time of injury.
The following evaluations and assessments will be performed:
Start and stop times of each infusion; record bottle changes
Recording ofanydeviation [greater than 30
minutes] from thespecified dosing times (1-
hour loading dose, then 119- hour maintenance infusion) and assigned infusion rates
Progesterone level sampling (allsubjects onDay 2(48+/-6 hours after initiation ofthe
study drug
infusion) ; additional sampling on PK subjects only )
Daily GCS (best), if possible to assess without interfering with the subject’s condition (if
sedation isdeemed necessary formedical reasons itshould notbe(temporaril y)halted
just t o assess GCS)
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 25of53 Amendment 3 November 15, 2011ICP, TIL forICPmanagement, andvital signs: The ICP, TIL andvital signs [heart rate
(bpm), respiration rate (per min), systolic and diastolic blood pressure (mm Hg),
temperature (Cº) andpupil response] will berecorded at00:00, 06:00, 12:00and18:00
hrs(+/-30 minutes). Inaddition ICP, TIL and vital signs will be recorded whenever ICP
management changes. If the I CP monitor is not placed, vital signs will still be collected.
ABGs : Dail y while the subject is intubated, as described in Section 6.1
Daily fluid balance
Neuroworsening assessment, if applicable
Concomitant medications and procedures
AEs
SAEs
Pre-injury narrative forGOS
assessment: complete nolater than 14dayspost-
randomization
6.4 Day 6: End-of-Infusion Evaluations
GCS (best), if possible to assess (see Section 6.3)
End
-infusion CTscan (+/-1 dayscheduled atthediscretion oftheInvestigator ).Itis
recommended thattheCTscan becompleted atornear theendoftheinfusion; however,
if the Investigator deems it necessary to obtain the CT scan on Day 5, this is acceptable.
Full phy sical examination including bod y weight
ICP, TIL, and vital signs, including pupil responses
Local labassessments (see Appendix Bfordetails) within 1hour after study drug
infusion iscompleted (Apregnancy testforwomen ofchild- bearing potential isnot
required on Day 6)
ABGs : While the subject is intubated, as described in Section 6.1
ECG
Daily fluid balance
Concomitant medications and procedures
Neuroworsening
assessment, if applicable
AEs (to be collected through Day 15)
SAEs
6.5 Day 1 5: Post -Infusion Evaluations /Discharge
Day 15assessments must becompleted 15days post-injury , +5 daysoratICUdischarge,
whichever occurs earlier.
GCS (best), if possible to assess (see Section 6.3)
Local labassessments (see Appendix Bfordetails) (Apregnancy testforwomen of
child- bearing potential is not required on Day 15)
Concomitant medications and procedures
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 26of53 Amendment 3 November 15, 2011Dates of ICU discharge and hospital discharge
Neuroworsening assessment, if applicable
AEs
SAEs
6.6 Day 30 (Month 1) Assessments
Day 30 assessments must be completed 30 day s post- injury , +2 day s.
Subject status, including mortality and dates of ICU discharge and hospital discharge
SAEs
6.7 Day 90 (Month 3) Assessments
Day 90/Month 3assessments should becompleted 90dayspost-injury , +14days,during anin-
person visit.
Subject status, including dates of ICU discharge and hospital discharge
GOS and GOS -E
SF-36 (must be complet ed by the subject)
SAEs
6.8 Day 180 (Month 6) Assessments
Day 180/Month 6assessments should becompleted at180dayspost-injury +28days,during an
in-person visit.
Subject status, including mortality and dates of ICU discharge and hospital discharge
GOS
and GOS -E
SF-36 (must be completed by the subject)
SAEs
6.9 Progesterone Blood Sam pleCollection
Blood will becollected byvenipuncture on Day 2 (48 +/- 6 hoursafterinitiation ofthestudy
drug infusion) foreach subject fordetermination ofprogesterone levels bytheCentral
Bioanal ytical
Laboratory .
Atselected sites (10-15US-based sites) ten(10) serial blood samples forpharmacokinetics (PK)
analysiswill be collected at the following times relative to the beginning of the infusion: 1, 8, 24 ,
48, 56, 72, 96, 104, 120, and 138 hours.
Theblood samples willbetaken from thearmnotused forthestudy druginfusion. Guidelines
forsample preparation, storage, packaging, andshipping willbeprovided totheInvestigator by
theCentral Bio analyticalLaboratory .
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 27of53 Amendment 3 November 15, 20117. ASSESSMENTS OF EFFIC ACY AND SAFETY
7.1 Efficacy Param eters
The following primar yand secondary efficacy parameters will beassessed inthistrial. These
endpoints are described in detail in Section 7.3.
Primary :GOS assessment at Month 6 post -injury
Secondary (all timepoints are post -injury ):
Mortality atMonth 1 and 6
GOS at Month 3
GOS -E at Months 3 and 6
SF-36 at Months 3 and 6
ICP, CPP and TIL
Comparison of CT scans at admission and end- infusion Day 6 (+/-1 Day )
7.2 Safety Param eters
Safety andtolerability willbedetermined byAEs, ECGs, safet ylabs, vital signs, fluid balance,
ABGs, and neuroworsening .
7.2.1 Adverse Events and Serious Adverse Events
Adverse events whether reported, observed, orelicited byindirect questioning will becaptured
from thetime ofinfusion start through 10dayspost-infusion (Day s1-15). SAEs will be
captured from
the time of infusion start throughout the c ourse of the subject’s participation in the
study (6months). TheAE/SAE relationship tothestudy treatment willbe judged asnotrelated,
possibly related, probably related, orrelated. Ongoing AEs willbefollowed toresolution,
whenever possible.
Particular attention should bepaid tothefollowing potential risks previously identified as
associated with administration ofprogesterone: serious thromboembolic events such as
thrombotic myocardial infarction, pulmonary embolism, deep vein thrombosis, ischemic stroke;
allergic reactions; marked liver function abnormalities; serious infections such aspneumonia,
sepsis, meningitis.
AllSAEs will be reported by telephone orwritten report within 24 hours of being notified of the
event totheSponsor’s MedicalMonitor and then reported toeach site's IRB/IEC according to
thelocal regulations . Serious adverse events thatpersist atMonth 6post-injury willbe
documented as to their final status.
7.2.2 ECG
The ECGs will beanalyzed atthesiteanddocumented ontheCRF by theInvestigator .All
clinically significant abnormal ECGs , assessed for clinical relevance by the Investigator ,must be
documented
as an AE on the CRF.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 28of53 Amendment 3 November 15, 20117.2.3 Laboratory Safety Tests
Standard clinical safety labswill bemeasured locally atthesites andrecorded forthespecified
time points (see Appendix Bfordetails). TheInvestigator willassess allabnormal labvalues at
these time points for clinical significan ce;ifcategorized as adverse events , they will be collected
and recorded similarl ytoother AEs.Allclinically significant abnormal labvalues will be
followed until resolution, whether ornotthey aredeemed AEs bytheinvestigator. Ifresolution
is not seen, a justification as to the cause for such an abnormalit y, such asif due to an underly ing
pre-existing condition, associated co- morbidit y, etc, willberecorded.
7.2.4 Vital Signs
Vital signs ( heart rate (bpm), respiration rate (per min), sy stolic and diastolic blood pressure (mm
Hg), and temperature (Cº), andpupil response) will bemonitored in parallel with andperthe
same timing as ICP and TIL (Sections 7.3.4 and7.3.5 below).
7.2.5 Daily
Fluid Balance
The total amount offluids administered andthetotal excreted once per24hour period will be
recorded during Day 1 through Day 6.
7.2.6 Arterial
Blood Gases
While the subject is intubated, the highest value of the day for the PaCO 2and the lowest value of
the day for PaO 2, pH, HCO 3and SaO 2along with the accompany ing Fio 2setting will be recorded
before randomization (Day 1 pre -dose) and daily during Day 1 through Day 6.
7.2.7 Neuroworsening
Instances ofneuroworsening will berecorded dailyfrom Day 1through Day 15.
Neuroworsening isdefined asanyoneofthefollowing: adecrease inGCSmotor score ≥2,
development ofpupillary abnormalities, anyother neurological deterioration orprogression of
lesion on CT scan leading to a change in patient management.
7.3 Selection of Efficacy Measurem ents Related To Managemen t of TBI
7.3.1 Glasgow Outcom e Scale (GOS)
TheGOS (Jennett andBond, 1975) istheprimary endpoint ofthisstudy andassesses mortality
anddisability inTBI patients according tothedesignation Good Recovery ,Moderate Disability ,
Severe Disability ,Vegetative State orDead. TheGOS will beadministered using astandard
questionnaire andaccompany ingnarratives at3and6months post-injury .A baseline narrative
will also berecorded bytheInvestigator. Acentral review will beperformed ofallGOS
recordings.
7.3.2 Glasgow Outcom e Scale -Extended (GOS -E)
The GOS -Ewill beadministered at3months and 6months post injury .A standardized
questionnaire structuring theinterview will beused, aswell asthenarrative completed bythe
Investigator. A central review will be performed of all GOS -E recordings.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 29of53 Amendment 3 November 15, 2011TheGOS -Eassessment ofmortality anddisability inTBI patients extends theoriginal five GOS
categories offunctional outcome toeight categories (Jennett etal.,1981; Wilson etal.,1998;
Teasdale et al., 1998):
Dead
Vegetative
State
Lower Severe Disabilit y
Upper Severe DisabilityLower Moderate Disability
Upper Mo derate Disability
Lower Good Recovery
Upper Good Recovery
7.3.3 Mortality
Any SAEwhich results indeath atanytime during thestudy willberecorded both asanSAE
andaDeath Report. TheDeath Report willinclude theprimary cause ofdeath, secondary cause
ifany,andthedate andtime ofdeath. Ifanautopsy isperformed, thereport should becollected
and provided in a de -identified manner.
7.3.4 Intracranial Pressure/Cerebral Perfusion Pressure
IfanICPmonitor isplaced, ICP measures will berecorded asearlyasbefore randomization
(Day 1 pre-dose, or as soon asthemonitor isplaced) andforupto6dayswhileICPisbeing
monitored. The ICPwill berecorded daily atthespecific times of:00:00, 06:00, 12:00 and
18:00 hour (+/-30minutes), along with vital signs [heart rate(bpm), respiration rate(per min),
systolic anddiastolic blood pressure (mm Hg), temperature (Cº) andpupil response ].Inadditi on
tothe4daily timepoints, ICPand vital signs will berecorded whenever ICP management
changes. IftheICP monitor isnotplaced, vital signs will still becollected atthese four
timepoints per day .
ICP will bemonitored p referentiall yusing acathet erconnected toanexternal s train gauge
(intraparench ymalICPdevice or ventricular catheter fortheICPmeasurement ).Ifplacement of
anintraventricular catheter isnotpossible, anintraparench ymalcatheter placed away from the
lesion may beused. Thetiming andduration ofICPmonitoring willbeatthediscretion ofthe
Investigator.
The CPP will becalculated automatically asthedifference ofmean
arterial pressure andICP,
based on the blood pressure and ICP readings recorded in the eCRF.
7.3.5 Therapeutic Intensity Level (TIL)
TILdata willberecorded forupto6daysorwhile ICPisbeing monitored .TILscores willbe
automatically calculated based onthemedications andprocedures used tomanage thesubject’s
ICP, asrecorded intotheeCRF. Table 1lists thespecific known treatments commonly usedto
manage ICPandCPP andthecorresponding scoring system (modified from Maset etal.,1987).
Ifno therapies were utilized , then the scoring i s zero during a given time period.
Table 1
Therapeutic
Intensity Level Grading System
Therapy Score
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 30of53 Amendment 3 November 15, 2011Surgical Decompression 1
Barbiturate Induced Coma 1
Hypothermia for ICP reduction 1
Hyperventilation (pCO 2<30) 1
Pressor Administration (to keep CPP 60) 1
Hypertonic Saline 1
Mannitol 1
Ventricular Drainage 1
Paralysis Induction 1
Sedation 1
Maximum Total Score 10
TIL scores will be analyzed based on the therapies recorded. Because of the stepwise
progression of therapy (from sedation to barbiturate use), barbiturate administration or
surgical decompression constitutes a total score of 1 0when performed .
Modified from Maset et al., 1987
7.3.6 CT Scans
Abaseline CTscan willbeperformed before randomization aspartofeligibility assessment. A
follow -upCTscan willbeperformed end-infusion onDay 6 (+/-1day)post-injury toassess the
progression oflesion volume andbrain edema. Thefindings will beclassified inaccordance
with theMarshall criteria (Marshall etal.,1992). Baseline andDay 6(+/-1Day)CTscans will
be sent to the central reader, who will evaluate them for study analysis purposes only .
7.3.7 QOL SF -36
TheQuality ofLife (QOL) SF-36 questionnaire will beassessed at3and6months post injury .
TheSF-36isavalidated generic, easilyadministered survey ofpatient health consisting ofeight
scaled scores, which arethesums oftheresponses toquestions ineach section (
Ware and
Sherbourne, 1992; McHorney et al., 1993). Each
scale is directly transformed into a 1 -100 scale
on the assumption that each question carries equal weight. The eight sections are:
Vitality
physical functioning
bodily pain
gener al health perceptionsrole phy sical
role emotional
role mental
mental health
The 8scales canalso besummarized into twosummary scores forphysical andmental health,
respectivel y.The SF -36 must be completed by the subject.
7.3.8 Glasgow Com a Scale
TheGlasgow Coma Scale (Teasdale andJennett, 1974) willbeperformed before randomization
andonce daily(best) during Days1to6andonDay 15.TheGCS isaneurological scale which
aims togive areliable, objective way ofrecording theconscious state ofaperson .Apatient is
assessed against each ofthree criteria, eye,verbal andmotor responses, andtheresulting values
aresummed forthetotal GCS score .Thelowest possible total GCS is3(deep coma ordeath),
while
the highest is 15 (fully awake person).
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 31of53 Amendment 3 November 15, 20118. STATISTICAL PLAN
8.1 Sample Size Justi fication
Itisplanned torecruit atotal of1180 patients randomized ina1:1ratio toBHR -100 or placebo
(590 ineach treatment group) .Thissample sizeestimation isbased ontheuseofaproportional
odds model (Whitehead, 1993) toanalyzethe primary outcome variable, namel ythe
conventional 5-point GOS atsixmonths after injury .Assuming approximately 31% good
outcome,
21% moderate disability , 19% severe disability and29% combined vegetative state and
death, thetotal sample sizeof1180 subjects willgive 90% power todetect acommon odds ratio
of1.5
of improvement in outcome (i.e.10% effect size) atthe1%significance level (two-sided).
The baseline outcome distribution used isbased onthesix-month GOS outcome distribution
from thehead injury population with GCS 3-8intheprevious TBI Phase 3 trials inthe
International Mission forPrognosis andAnal ysisofClinical Trials inTBI Project (IMPACT)
Database (Marmarou et al., 2007).
8.2 Baseline Data
Baselin e comparability of the randomized groups will be illustrated using appropriate descriptive
statistics.
8.3 Prim ary Efficacy Analysis
The primary efficacy variable is GOS evaluated at 6 months post injury .
The proportional odds model (POM) (McCullagh, 1980) willbeused tocompare BHR -100 to
placebo fortheGOS outcome atsixmonths (categories ofgood recovery ,moderate disability ,
severe disability ,andthecombined vegetative state/death). A testfortheproportional odds
assumption will beconducted andifstatistically significant,
other polytomous logistic models
will beinvestigated. The analyseswill beconducted onanintent -to-treat (ITT ,i.e.all
randomized subjects) basis ,and thePOM will befitted i ncluding theeffect oftreatment,
geographic region (North America, Europe, Asia, andSouth America), age, GCS motor score,
pupil response, and CT classification.
Ifthep-value from thetestofthenullhypothesis islessthan0.0003 (attheinterim analysis)or
0.0098 (atthe
final analy sis), itwill beconcluded that BHR -100 isstatistically significantl y
different
from placebo with respect to the GOS at 6 months following injury .
Intheevent thattheprimary efficacy analysisdoes notshow statistical significance atthestudy
wise 1%significance level, i.e.thefinal analysisp-value isnotlessthan 0.0098, afinal adjusted
p-value willbecalculated andtheresult considered statistically significant atthe5%level ifthe
adjusted p-value islessthan 0.05.Theadjusted p-value willbecalculated using EAST(Cytel
Statistical Software, Cambridge, MA) orother appropriate statistical software package toadjust
for
the interim anal ysis usin g the pre -specified boundaries.
8.3.1 Alternate Prim ary Efficacy Analysis: Sliding Dichotomy Model
Iftheproportional odds assumption cannot bejustified, ananalysiswill beconducted using a
sliding dichotomy (Maas etal.,2006; Murray etal.,2005 )oftheGOS outcome at6months
following injury ,following categorization ofpatients i ntodifferent prognosis groups (worst,
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 32of53 Amendment 3 November 15, 2011intermediate, andbest) based onbaseline prognostic factors. Thehypothesis thattheproportion
offavorable responses observed ineach treatment group isthesame will betested both within
thebaseline prognosis grouping (best, intermediate andworst) andoverall using theCochran-
Mantel Haenszel Chi- Square test, adjusted for region.
Ifthep-value from thetestofthenullhypothesis ofnodifference intheproportion offavorable
responses observed ineach treatment group islessthan 0.0003 (attheinterim) or0.0098 (atthe
final analysis),itwill beconcluded that there isastatistically significantly difference inthe
proportion
of favorable responses between the 2 treatment groups.
If this anal ysis is not required as an alternate analy sis to the Proportional Odds Model analy sis, it
will still be performed as an additional sensitivity analysis.
8.3.2 Sensitivity Analysis: Dichotom ized Model
Inaddition, theGOS at6months post injury willbedichotomized into Good Recovery ,
Moderate Disability versus Severe Disability , Vegetative Status/Dead.
Thebinary outcome willbeanalyzedusing logistic regression analysis.Thelogistic regression
model will be fitted including the effect of treatment, geographic region (North America, Europe,
Asia, and South America), age, GCS motor score, pupil response, and CT classification.
Thelogistic regression model willbeused totestthenullhypothesis thattheodds ofan‘event’,
i.e.observing aresponse ofmoderate disability orgood recovery ontheoutcome variable, GOS
at6months following injury ,adjusted forregion, age, GCS motor score, pupil response, andCT
classification
is the same in both treatment groups, i.e.
Null Hy pothesis: H0: β1= 0
Alternative Hy pothesis: H1: β1≠ 0
Ifthep-value from thetestofthenullhypothesis of1=0islessthan 0.05, itwillbeconcluded
thatBHR -
100isstatistically significantly different from placebo with respect totheGOS at6
months following injury .Theodds ofan‘event’ (moderate disability ,orgoodrecovery )inthe
GOS at6months willbemodeled andthecorresponding common odds ratio fortreatment,1e,
canthen be interpreted to determine the direction of the treatment difference as follows: with the
placebo group being considered asthereference category ,iftheodds ratio (OR BHR -100/placebo )is
greater than 1,theodds ofafavorable outcome intheGOS at6months isgreater intheBHR -
100 treatment group compared to placebo.
8.3.3 Handling of Missing Prim ary Efficacy Endpoint Data
When theprimary efficacy endpoint ismissing, thelastobservation carried forward (LOCF)
principle will be used to populate the primary endpoint, i.e. the Month 3 GOS assessment will be
carried forward. Intheevent thatasubject hasneither the3northe6-month GOS, themissing
values would beimputed based upon theproportional odds model. Itisanticipated thatthere
will beminimal missing data, however sensitivity analyseswill becarried out, ifnecessary ,to
confirm thattheimputation method(s) did
nothave animpact ontheprimary efficacy analysis
results.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 33of53 Amendment 3 November 15, 20118.4 Secondary Endpoints and Exploratory Endpoints
Secondary efficacy parameters include:
1.Mortality at Month 6
2.Mortality at Month 1
3. GOS at Month 3
4.GOS -E at Month 6
5.GOS -E at Month 3
6.SF-36 at Month 6
7.SF-36 at Month 3
Exploratory parameters include:
1. Assessment of CT scans (admission vs. end- infusion Day 6 +/-1 Day )
2.ICP
3.CPP
4.TIL
These parameters are described briefly in the sections that follow.
8.4.1 Mortal ity Assessment at One and Six Months Post -injury
The mortalit yrateatone and sixmonths will becompared between thetwotreatment groups.
Thehypothesis that the mortality rateatonemonth (and at 6 months) observed in each treatment
group is the same will be tested using the Fisher’s Exact test. A two -sided, 5% significance level
willbeused totestthenullhypothesis. Ifrejected (p<0.05), itwillbeconcluded thatthere isa
statistically significant difference in the proportion of deaths between the 2 treatment groups.
The time from injury todeath will beanalyzed using Kaplan -Meier analysisand Cox
Proportional
Hazard Modeling.
8.4.2 Secondary Analyses of GOS at Three Months Post -injury
The GOS atthree months will beanalyzedfollowing thesame analy sesandprocedures forthe
primary efficacy analysisdescribed inSection 8.3.Thiswill provide ameasure offunctional
improvement between BHR -100 and placebo.
8.4.3 GOS -
Eat Three and Six Months Post -injury
The extended GOS isan8-point scale with thefollowing categories: Dead, Vegetative State,
Lower Severe Disability ,Upper Severe Disability, LowerModerate Disability ,Uppe rModerate
Disability , Lower Good Recovery , and Upper Good Recovery .
Thenullhypothesis thattheglobal assessment ofoutcome, asmeasured bytheGOS -E at 3or6
months, is the same in each treatment group will be te sted using the 2- sided Wilcoxon Rank- Sum
test,which can be obtained from the NPAR1WAY procedure in SAS®.
Atwo-sided, 5%significance level willbeused totestthenullhypothesis. Ifrejected atthe5%
level (p<0.05) ,itwill beconcluded that there isastatistically significant
difference inthe
global assessment ofoutcome between the2treatment groups, asmeasured bytheGOS -E.The
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 34of53 Amendment 3 November 15, 2011magnitude of the summary statistics will be examined to determine the direction of the treatment
difference.
8.4.4 Quality of Life using SF -36
Summary statistics for the 8 scales and the phy sical and mental composite summary scores of the
SF-36will be presented for each treatment group.
Inaddition tosummarizing thedata, thephysical and mental composite summary scores at
Month 3and 6will beanaly zed using ananaly sisofcovariance (ANCOVA) model. The
ANCOVA model
will include treatment group, ageasacovariate andthe stratification factors as
outlined fortheprimary efficacy analysis,name lyregion (North America, Europe, Asia, and
South America), GCS motor score, pupil response, and CT classification.
The null hypothesis that themean physical andmental summary scores arethesame for both
treatment groups (BHR- 100 and placebo) will be tested against the 2 -sided alternative hy pothesis
thatthemean physical andmental summary scores aredifferent ineach treatment group, atthe
0.05 significance level.
8.4.5 Exploratory Clinical Parameters: ICP, CPP and TIL
Impact ofstudy treatment onthree clinical assessment parameters -ICP,CPP andTIL-willbe
analyzed. Please also refer to the Statistical Analysis Plan (SAP) for further details.
ICP: IfanICPmonitor is placed, the ICP will be recorded dail yatdesignated timepoints,
aswell aswhenever ICPmanagement changes (see Section 7.3.4) uptosixdayspost
admission. These
data will be summarized descriptively for each treatment group.
CPP: CPP will becalculated from blood pressure and ICP readings. Datawill be
summarized descriptively foreach treatment group. Summary statistics ofthenumber of
non-missing observations, absolute andrelative frequency ofCPP measurements inthe
following categories willbepresented foreach treatment group: lessthan 50mmHg, 50-
60
mmHg, 60- 70 mmHg and greater than 70 mmHg.
TIL:The therapies used forICPmanagement will becalculated based onthetime that
each therapy wasreceived. Thepercentage oftime each therap yisused will be
calculated for each 24 -hour period post dosing and for all time periods. The hours of use
for each therap y will be summarized descriptively for each treatment.
8.4.6 Exploratory Param eter: CT Scan
Effect ofstudy treatment ontheprogression ofintracranial pathology willbeassessed bya
central reader from baseline (admission) andend-infusion Day 6(+/-1Day)CTscans toassess
the progression oflesion volume andbrain edema. Thefindings willbeclassified inaccordance
with th e Marshall classification.
No patient is expected to have CT classification I, as this indicates a normal CT scan.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 35of53 Amendment 3 November 15, 2011Thenumber ofnon-missing observations, absolute andrelative frequency (nandpercentages)
will
be tabulated by treatment group. The magnit udeofthe summary statistics will be examined
to determine the direction of the treatment difference.
8.5 Adverse Event Safety Data
Data on adverse events will be presented descriptively , grouping events by body system. Results
will bepresented foralladverse events, including instances ofneuorworsening andabnormal
clinically significant laboratory findings deemed as AEs by the Investigator.
The occurrence ofadverse events will becompared between treatment groups, including the
proportion ofsubjects ineach arm suffering atleast oneepisode oftheevent aswell asthe
comparison ofthe distribution ofthe number ofoccurrences ofthe event. Additional
presentations of AE data may berequested bytheData andSafet yMonitoring Board (DSMB)
(see Section 10.4).
8.6 Interim Analysis
Aformal interim analysiswillbeperformed once 200subjects ineach treatment arm(400total
subjects ) have completed the study , i.e. have been assessed for the6-month GOS.
8.6.1 Interim Analysis for Efficacy
Attheplanned interim analy sis,theteststatist icbased ontheeffect size (common odds ratio)
will be compared to the critical value shown below. If the test statistic exceeds the critical value,
continuation ofthetrial will beevaluated. Inorder tostop thetrial attheinterim analysis,the
significance level will need to be less than the critical p- value.
At the planned interim analy sis, a two -sided test will be performed to detect either an increase or
decrease inthecommon odds ratio. In order topreserve theover-alltypeIerror rateat1%, the
critical value fortheteststatistic willbeinflated above 2.575, thevalue thatwould beused ifno
repeated testing were used (Table 2).Theactual critical values andp-values will becomputed
using statistical
methods for group sequential testing with the O’Brien Fleming method (O’Brien
and Fleming, 1979; Lee and Quan, 1993) .
Table 2
Critical Values and p -Values for Planned Interim Analysis
Interim and
Final AnalysesTotal Sample Critical
Valuep-value Cumulative
Type I Error
Interim ( 1) 400 3. 65 0.0003 0.0003
Final ( 2) 1180 2.58 0.0098 0.0101
8.6.2 Futility Analysis
Under thecondition thattheproportional odds model assumption holds, thestatistical power to
reject the null h ypothesis of equal six -month GOS is shown below under a variet y of scenarios.
Conditional power istheestimate ofthepower toobserve adiffe rence in treatment groups
different from thatobserved attheinterim analysis.Theconditional power iscalculated based
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 36of53 Amendment 3 November 15, 2011upon theobserved critical value andmeasure ofthecompletion ofthetrial. Methods forthis
calculation have been proposed byLan,DeMets and Halperin (1984) and Lan, Simon and
Halperin (1982) (Table 3).
Table 3
Futility
Analysis: Power to Reject Null Hypothesis under Various Scenarios
1A common odds ratio of 1.27, 1.5 and 2.33 is equivalent to a 5%, 10% and 20% effect size respectively.
2Interim analysis is based on the assessment of 400 completed subjects (200 in each arm).
3Final analysis is based on total study recruitment at 1180 subjects with 590 in each arm. This sample size is
calculated based on the defined baseline outcome distribution (30% GR, 21% MD, 19% SD and 30% VS/D) to
detect a common odds ratio of 1.5 of i mprovement in outcome with 90% pow er and 1% significance level (tw o-
sided).
8.6.3 Outcom es of Interim Analysis
If the p -value from the test of the null hy pothesis of no treatment difference is less than 0.0003 at
the interim anal ysis, the study could be stopped for efficacy .
Noformal stopping rule forfutility willbeestablished forthis study. Anassessment of
conditional power attheinterim analy siswill beprovided totheDSMB forconsideration with
the safet y summaries in the evaluation of the overall risk/benefit of the study treatment.Common odds ratio1Power at interim and final analysis
Placebo BHR -100 Interim analysis2Final analysis3
1.0 1.27 1.54% 39.36%
1.0 1.50 10.93% 90.66%
1.0 2.33 88.49% 99.99%
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 37of53 Amendment 3 November 15, 20119. ADVERSE EVENT COLLECTION AND REPORTING
9.1 Adverse Event Collection
AllAEs will be recorded for the first 15days after the start of administration of thestudy drug (5
daysofdrug infusion and10dayspost infusion). SAEs willberecorded fortheentire 6 -month
period. The Adverse Events eCRF must be completed for all reported AEs and SAEs.
Anadverse event isdefined as:“Anyuntoward medical occurrence inasubject orclinical
investigation subject administered apharmaceutical product that does notnecessarily havea
causal relationship with thistreatment.” Anadverse event cantherefore beanyunfavorable and
unint ended sign (including anabnormal laboratory finding), symptom, ordisease temporall y
associated with theuseofamedicinal (investigational) product, whether ornotrelated tothe
medicinal (investigational) product. Thisincludes anynewl yoccurring eventorprevious
condition that hasincreased inseverit yorfrequency since theadministration ofstudy drug.
Instances of neuroworsening are considered AEs.
Details ofanyadverse orunexpected events, signs, andsymptoms will becollected including
detai lsofonset, resolution, frequency ,severit y(asdefined below), seriousness, relationship to
thedrug, effect onthestudy drug, treatments administered, and outcome. AnyAEwillbe
followed, whenever possible, until itreturns tothebaseline condition orbecomes stable with no
further change expected.
9.2 Reporting of Adverse Event s
Diagnoses vs. signs/s ymptoms:
Each AEshould berecorded torepresent asingle diagnosis .Accompany ingsigns(including
abnormal laboratory values ifnotconstituting AEs themselves orECG findings) orsymptoms
should NOT berecorded asadditional AEs. Ifadiagnosis isunknown, sign(s) orsymptom(s)
should be recorded as an adverse event(s).
Laboratory values and ECG findings:
Changes in laborator yvalues or ECG parameters may beconsidered AEs if they are judged to be
clinically significant (i.e., ifsome action orintervention isrequired oriftheInvestigator judges
thechange tobebeyondtherange ofnormal physiological fluctuation). Clinicallysignificant
abnormal labvalues notconsidered AEs bytheInvestigator will befollowed asindicated in
Section 7.2.3. Ifabnormal laboratory values orECG findings aretheresult ofpathology for
which thereisanoverall diagnosis (e.g., increased creatinine inrenal failure), thediagnosis only
should
be reported as an AE.
Pre-existing conditions:
Pre-existing conditions (present before thestart oftheAEcollection period) areconsidered
concurrent medic alconditions andshould NOT berecorded asAEs. However, ifthesubject
experiences aworsening orcomplication ofsuch aconcurrent condition, theworsening or
complication should berecorded asanAE. Investigators should ensure that theAEterm
recor ded captures the change in the condition (e.g., “worsening of….”).
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 38of53 Amendment 3 November 15, 2011Preplanned surgeries or procedures:
Preplanned procedures (surgeries ortherapies) thatwere scheduled prior tothestart ofadverse
event collection are not considered AEs. However, if apreplanned procedure is performed early
(e.g.,asanemergency )duetoaworsening ofthepreexisting condition, theworsening ofthe
condition
should be captured as an AE.
Elective surgeries or procedures:
Elective procedures performed where there isnochange inthesubject’s medical condition
should not be recorded as AEs, but should be documented in the subject’s source documents.
Insufficient clinical response (lack of efficacy ):
Insufficient clinical response, efficacy , or pharmacological action, shou ld NOT be recorded as an
AE. The Principa lInvestigator must make thedistinction between exacerbation ofpre-existing
illness and lack of therapeutic efficacy .
Overdose :
Cases of drug overdose without manifested side effects are NOT considered AE s.
Relationship to Study Drug:
The AE/SAE relationship tothestudy treatment will bejudged asnotrelated, possibly related,
probably related, or related. Itshould be noted that the half -life of progesterone in BHR -100 was
found tobe5.30 hrs(SD 0.66) inBHR’s Phase 1trial ofhealthy male subjects, with
progesterone largel ycleared b y 24 hours.
9.3 Assessment of Adverse Event Severity
The following guidelines for rating severity of adverse events should be used:
Mild:
Awareness ofsigns orsymptoms, buteasily tolerated; areofminor irritant type;nolossoftime
from normal activities; symptoms would notrequire medication oramedical evaluation; signs
and sy mptoms may be transient, disappearing during continued trea tment with study medication.
Moderate:
Discomfort enough tocause interference with usual activities; thestudy medication may have
been interrupted.
Severe:
Incapacitating with inability to do work ordousual activities; signs andsymptoms may beof
systemic nature orrequire medical evaluation; thestudy drugmay havebeen stopped, and
treatment for the event may be required.
The term “severe” is often used to describe the intensity of a specific event, as in mild, moderate,
orsevere myocardial i nfarction; theevent itself, however, may beofrelatively minor medical
significance, such assevere headache. Thisisnotthesame asserious, which isbased on
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 39of53 Amendment 3 November 15, 2011subject/event outcome oraction criteria usuall yassociated with events that pose athreat toa
subject’s life or functioning. The Investigator must decide whether each AE meets the definition
of an SAE.
9.4 Serious Adverse Events and Expedited Reporting
An SAE is any untoward medical occurrence that at any dose:
Results in death.
Islife-threatening. Life-threatening, inthedefinition ofserious, refers toanevent in
which the subject was at risk of death at the time of the event; it does not refer to an event
which hy potheticall y might have caused death if it were more severe.
Requires inpatient hospitalization or prolongation of existing hospitalization.
Results in persistent or significant disability /incapacity .
Is a congenital anomal y/birth defect.
Isconsidered medically significant bytheInvestigator orrequires intervention toprevent
any oneoftheoutcomes above. Medicall ysignificant arethose events considered
important intheInvestigator’s opinion that may notbeimmediatel ylife-threatening or
result indeath orhospitalization but may jeopardize thesubjec tormay require
intervention toprevent oneoftheother outcomes listed inthedefinition above. These
will also usually be considered serious.
AllSAEs willberecorded from thetime ofthestart ofthestudy infusion through thesubject’s
participatio ninthestudy (6months). TheMedical Monitor must benotified within 24hours.
AllSAEs should bemonitored until they areresolved orareclearl ydetermined tobeduetoa
patient’s stable or chronic condition or intercurrent illness(es).
Cause ofdeath isrequired whenever known. Ifanautops ywas performed, anautops yreport
should
be provided. Death should usually be reported as the outcome of a specific SAE.
Reports forhospitalization of elective procedures do not need to be reported as SAEs i fthere are
noprecipitating signs/symptoms orworsening ofapre-existing condition thatnecessitated the
procedure. However, SAEs must bereported foranycomplications resulting from aprocedure
that prolonged the hospitalization.
The following isalistofevents that areanticipated tooccur inthetargeted severe TBI
population, in the absence of study drug.
hypoxemia
hypotension
dyspnoea
increased ICP
pneumonia
sepsis
cerebral infarction
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 42of53 Amendment 3 November 15, 201110. REGULATORY AND PROCE DURAL REQUIREMENTS
10.1 Ethical Conduct of the Study
Good Clinical Practice (GCP) isaninternational ethical and scientific quality standard for
designing, conducting, recording, andreporting studies thatinvolve theparticipation ofhuman
subjects .Thisstudy willbeconducted incompliance with GCP andtheapplicable national
regulations so as to assure that the rights, safet y, and wellbeing of the participating study subjects
areprotected consistent with theethical principles that have their origin intheDeclaration of
Helsinki.
10.2 Independent Ethics Committee or Institutional Review Board
The Sponsor (oranauthorized representa tive) ortheInvestigator (according tonational
provisions) isresponsible forfollowing theregional lawwhere thestudy istobeconducted to
obtain written approval fortheclinical study protocol (including a llsubstantial protocol
amendments), the subject informed consent (including written assent, when applicable),
informed consent updates, subject recruitment procedures (e.g., advertisements) andanyother
information tobeprovided to subjects from anIEC/I RBthatcomplies with thelocal regulatory
requirements.
Written approval ofthestudy mustbeobtained from theIEC/IRBprior tothestudy being
implemented (i.e., shipment ofclinical supplies totheInvestigator orscreening ofsubjects).
Copies oftheapproval documentation will bemaintained byboth theInvestigator and the
Sponsor (or an authorized representative) in the designated study documentation files.
The Sponsor (oranauthorized representative) ortheInvestigator (according tonational
provisions) will submit written reports oftheclinical study status totheIEC/IRB annually ,or
more frequentl yifrequested bytheIEC/IRB. Afinalstudy notification should beforwarded to
theIEC/I RBwithin 90daysafter thestudy hascompleted, orintheevent ofpremature
termination ofthestudywithin 15days,with therationale forstudy termination clearl y
explained. Copies of all clinical study status reports (including termination) willbemaintained
byboth theInvestigator and theSponsor (oranauthorized representative) in thestudy
documentation files.
Inaccordance
with national provisions and the rules of the Food and Drug Administration (FDA),
European Parliaments Clinical Trial Directive, orapplicable national orstate laws, theSponsor
(oranauthorized representative) will inform allparticipating IECs/I RBs andnational authorities
ofallSAEs orother safety- related i nformation, which occur during theclinical study as
appropriate.
10.3 Subject Information and Consent
Aspatients in thisstudy willnotbeable toprovide informed consent atbaseline duetoclinical
status, informed consent will beobtained following theregional lawwhere thestudy isbeing
conducted, under theguidance oftheIRB/IEC while remaining fully compliant with ICH
guidelines .
TheInvestigator is responsible for assuring the appropriate content of the informed consent form
andthatinformed consent isobtained foreach subject in accordance with theapplicable local
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 43of53 Amendment 3 November 15, 2011regulations andguidelines. The original signed informed consent istoberetained in thestudy
documentation files.
TheInvestigator shall maintain alogofallsubjects forwhom informed consent isobtained and
indic ateifthesubject received study drug or, ifnot, thereason why.Thesubject’s medical
records should also document thattheinformed consent was obtained, including date andtime,
and that the appropriate local legal requirements regarding informed con sent were followed.
TheInvestigator will give the subject’s LAR information about thetrial inaform thattheLAR
canread andunderstand. IftheLAR isunable toread, oralinformation onthetrial willneed to
beprovided totheLAR using thePatient Information Sheet inthepresence ofawitness, if
applicable, according to regional law.
Informed consent will beobtained forthistrial intwophases: First,where applicable bylocal
law, aLAR orother authorized representative may provide consent andsecond, subjects may
provide consent later ifandwhen they become capable ofself-consent. Thesubject (and/or the
subject’s LAR) will beinformed thathe/she could withdraw from thetrial atanytimeforany
reason.
Thesubject will be informed about thetrial ifandwhenever he/she becomes competent togive
anopinion on continuation inthetrial, and thesubject will begiven theopportunity towithdraw
from thetrial.Ifthesubject consents tocontinue inthetrial, the subject will berequested to
record consent bysigning theSubject Informed Consent Form .Ifconsent isdenied bythe
subject, thesubject will beimmediatel ywithdrawn from thetrial. Ifasubject dies before
becoming able to consent, then the above rights to trial data will rem ain with the L AR.
10.4 Data Safety Monitoring Board
Anindependent DSMB willbeappointed tohave responsibil ityforsafeguarding theinterests of
trial subjects,andassessing thesafet yandefficacy ofthestudy treatments during thetrial. The
DSMB’s assessments will bebased onsafety andefficacy dataperiodically senttotheDSMB
statistician atapproximately 100-subject intervals, with precise interval stobedetermined in
consultation with theDSMB. TheDSMB will have theauthority to
recommend stopping the
trial at an y point based upon stopping rules agreed upon with the Sponsor.
Based on its review, the DSMB might also provide the Sponsor with recom mendations regarding
study modification. The DSMB will consist of independent clinicians andbiostatisticians that,
collectively ,have experience inthemanagement ofpatients with TBI andintheconduct and
monitoring ofrandomized clinical trials. The DSMB will function inaccordance with a
dedicated charter and the study protocol.
10.5 Steering Committee
ATBI Steering Committee, composed ofmembers ofAmerican Brain Injury Consortium
(ABI C)andEuropean Brain Injury Consortium (EBIC), andother experts inthefields ofTBI
clinical research, provides scientific andacademic leadership forthisstudy inconsultation with
the Sponsor. The goals and study design have been endorsed b y ABIC and EBIC.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 44of53 Amendment 3 November 15, 201110.6 ABIC (American Brain Injury Consortium )
ABIC isagroup ofdistinguished neurosurgeons and clinicians dedicated toimproving the
outcome ofbrain injury patients, and whose mission istoincrease the scientific merit ofTBI
clinical trials.
ABIC Quality Review :
Forqualit yassurance purposes, ABICwill review clinical data intheeCRF ofselected tr ial
subjects toensure thatallmedications andprocedures required totreat the subject’s TBI were
administered according to the study protocol.
Based onitsQualit yReview, ABIC will provide theSponsor oritsdesignee with Quality
Review Reports regarding clinical sites’ compliance with the study protocol.
10.7 Investigator Obligations
The Principal I nvestigator agrees toconduct theclinical study incompliance with thisprotocol
which was approved bytheIEC/IRB incompliance with local regulatory requirements. The
Investigator and the Sponsor will sign the protocol (Page 2) to confirm this agreement.
10.8 Electronic Case Report Forms (eCRFs)
Data collection forthisprotocol will beaccomplished using anElectronic Data Capture system
(EDC). Therefore, the term eCRF will be utilized.
eCRFs arerequired andmust becompleted foreach randomized subject. ItistheInvestigator’s
responsibility toensure theaccuracy ,completeness, ,andtimeliness ofthedata reported onthe
subject’s eCRF. eCRFs should becompleted inatimely fashion tosupport thestudytimelines.
Source documentation supporting the eCRF data should indicate the subject’s participation in the
study andshould document thedates anddetails of informed consent, study procedures, adverse
events, andstatus. TheInvestigator ordesignee should complete andthe Investigator should
verify thesource documents astheinformation iscollected. Completed case report forms must
besubmitted foreach randomized subject. TheInvestigator will retain acopy ofallcompleted
source documents.
10.9 Monitoring the Study
Site visits andinspections will beconducted bytheSponsor ordesignee atregular intervals in
accordance with FDA andInternational Conference onHarmonization (ICH) guidelines. The
Investigator will permit representatives ofthesponsor’s monitoring team, FDA orlocal health
authority auditors to inspect facilities and records relevant to this study .
10.10 Protocol Deviations
The Investigator will make every attempt toavoid deviat ions from theprotocol, except in
medical emergencies. Intheevent ofamedical emergency ,theMedical Monitor must be
notified as soon aspossible. Thegoverni ngIRB/IEC will beinformed ofallprotocol changes
issued bytheSponsor bytheinvestigator inaccordance with theIRB/IEC’s established
procedure .
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 45of53 Amendment 3 November 15, 201111. DATA HANDLING AND RE CORDKEEPING
11.1 Disclosure of Data
Individual subjects’ medical information obtained asaresult ofthis study isconsidered
confidential anddisclosure tothird parties other than those noted below isprohibited. Subject
confidentiality willbefurther assured byutilizing subject identification code numbers. Ifresults
ofthisstudy arereported
inmedical journals oratmeetings, thesubject’s identity willremain
confidential. Medical information may beprovided tothesubject’s personal physician orto
other appropriate medical personnel responsible for the subject’s welfare.
Data generated as a result of this study are to be available for inspection on request by FDA/local
health authorit yauditors, thesponsor’s monitors, andbytheIRBs/IECs. IftheFDA orother
regulatory agency should schedule aninspection, theMedical Monitor should beadvised
immediately .
11.2 Publication
Bysigning thestudy protocol, theInvestigator agrees thattheresults ofthestudy maybeused
forthepurposes ofnational and international registration, publication, and information for
medical and pharmaceutical professionals by the Sponsor .
Publications orpresentations based onthestudy maynotbemade until thestudy iscompleted,
unless sodecided bytheSponsor. Once theSponsor ordesignee publishes thefinal report and
main study manuscript, orifpublication hasnotoccurred within 18months aftercompletion of
thestudy (final database lock), anInvestigator may individually publish orpresent information
onthis study ,preferably providing the manuscript tothe Sponsor forreview prior to
publication. The Clinical Trial Agreement between theInvestig ator and theSponsor may
provide additional terms regarding publication or presentation based on the study .
11.3 Record keeping and Retention
The Investigator must maintain adequate records forthestudy including completed case report
forms, medical records, laboratory reports, signed informed consent documents, drug disposition
records, adverse experience reports, information regarding subjects who discontinued, all
correspondence with the IRB/IEC and the spon sor, and other pertinent data.
Allrecords aretoberetained by theInvestigator foraminimum period of2years after the
United States Food and Drug Administration/local health authority approves theNew Drug
Application (NDA); oraminimum period of2yearsfollowing thetermination orwithdrawal of
the health regulatory agency exemption (e.g., Investigational New Drug (IND) orclinical trial
application) under which the study was conducted. To avoid any possible errors, the Investigator
must contact the Sponsor prior to the destruction of any study records. The I nvestigator will also
notify the Sponsor in the event of accidental loss or destruction of any study records.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 46of53 Amendment 3 November 15, 201112. REFERENCES
American Brain Injury Consortium. (2003). ABIC Patient Care Guidelines. October 7,
2003. http://www.abic.vcu.edu/guidelines/abicguidelines.cfm
Brain Trauma Foundation (BTF), American Association of Neurological Surgeons,
Congress of Neurological Surgeo ns,Joint Section on Neurotrauma and Critical Care,
AANS/CNS,
Bratton , S.L., Chestnut , R.M., Ghajar , J.,et al.(2007). Guidelines for the
management of severe traumatic brain injury .J. Neurotrauma. 24 Suppl 1, S77- 82.
Brown, A.W., Elovic, E.P., Kothari, S., Flanagan, S.R., and Kwasnica, C. (2008).
Congenital and acquired brain injury . 1. Epidemiology , pathoph ysiology , prognostication,
innovative treatments, and prevention. Arch. Phys. Med. Rehabil., 89 (Suppl 1), S3-8.
Cutler, S.M., Cekic, M., Miller, D.M., Wali, B., VanLandingham, J.W., Stein, D.G., et al.
(2007). Progesterone improves acute recovery after traumatic brain injury in the aged rat. J.
Neurotrauma ,24(9) , 1475 -1486.
Cutler, S.M., Pettus, E.H., Hoffman, S.W., Stein, D.G. (2005). Tapered progesterone
withdrawal enhances behavioral and molecular recovery after traumatic brain injury .Exp.
Neurol .,195(2) , 423- 429.
Cutler, S.M., VanLandingham, J.W., Murphy, A.Z., Stein, D.G. (2006). Slow- release and
injec ted progesterone treatments enhance acute recovery after traumatic brain injury .
Pharmacol. Biochem. Behav .84(3), 420-428.
Djebaili,
M., Guo, Q., and Pettus, E.H. (2005). The neurosteroids progesterone and
allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain
injury in rats. J. Neurotrauma, 22, 106-118.
Djebaili, M., Hoffman, S.W., and St ein, D.G. (2004). Allopregnanolone and progesterone
decrease cell death and cognitive deficits after a contusion of the rat pre- frontal cortex.
Neurosci., 123, 349-359.
Duvdevani,
R., Roof, R.L., and Fulop, Z. (1995). Blood-brain barrier breakdown and ed ema
formation following frontal cortical contusion: does hormonal status play a role? J.
Neurotrauma, 12, 65-75.
Faul, M., Xu ,L., Wald ,M.M., Coronado, V.G. (2010). Traumatic Brain Injury in the
United States: Emergency Department Visits, Hospitalizations and Deaths 2002 –2006.
Atlanta
(GA): Centers for Disease Control and Prevention, National Center for Inj ury
Prevention and Control .
Galani, R., Hoffman, S.W., Stein, D.G. (2001). Effects of the duration of progesterone
treatment on the res olution of cerebral edema induced by cortical contusions in rats. Restor.
Neurol. Neurosci .18(4), 161- 166.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 47of53 Amendment 3 November 15, 2011Gibson, C.L ., Gray , L.J., Bath, P.M.W., Murphy , S.P. (2008). Progesterone for the
treatment of experimental brain injury ; a systematic review. Brain . 131(Pt 2), 318-328.
Grossman,
K.J., Goss, C.W., and Stein, D.G. (2004). Effects of progesterone on the
inflammatory response to brain injury in the rat. Brain Res., 1008, 29-39.
Guo, Q., Say eed, I., and Baronne, L.M. (2006). Progesterone adminis tration modulates
AQP4 expression and edema after traumatic brain injury in male rats. Exper. Neurol., 198,
469-478.
He, J., Hoffman, S.W., and Stein, D.G. (2004). Allopregnanolone, a progesterone
metabolite, enhances behavioral recovery and decreases neu ronal loss after traumatic brain
injury .Restor. Neurol. Neurosci., 22, 19-31.
Hukkelhoven,
C.W.P.M., Stey erberg, E.W., Rampen, A.J.J., et al. (2003). Patient age and
outcome following severe traumatic brain injury : an anal ysis of 5600 patients. J.
Neuros urg., 99(4) , 666 -673.
Jennett, B., and Bond, M. (1975). Assessment of outcome after severe brain damage.
Lancet., 1(7905), 480-484.
Jennett, B., Snoek, J., Bond, M.R., Brooks, N. (1981). Disability after severe head injury :
observations on the use of the Glasgow Outcome Scale. J. Neurol. Neurosurg. Psychiatr .,
44(4), 285-293.
Lan,
K.K.G., DeMets, D.L., Halperin, M. (1984). More flexible sequential and non -
sequential designs in long- term clinical terms. Commun Statist -Theor. Meth. 13, 2339-2353.
Lan, K.K.G., Simon, R., Halperin, M. (1982). Stochasticall y curtailed tests in long -term
clinical trials. Commun. Stat. -Sequential Analysis, 1, 207-219.
Langlois, J.A., Rutland- Brown, W., and Wald, M.M. (2006). The Epidemiology andImpact
of Traumatic B rain Injury .J. Head Trauma Rehabil., 21(5), 375-378.
Lee, Y.J., and Quan, H. (1993). P- values after repeated significance testing: a simple
approximation method. Stat Med .,12(7), 675-684.
Maas,
A.I., Dearden, M., Teasdale, G.M., et al. (1997). EBIC- guidelines for management
of severe head injury in adults. European Brain Injury Consortium. Acta Neurochir (W ien).
139(4), 286-294.
Maas,
A.I.R., Murray , G., Henney , H., et al. (2006). Effica cyand safety of dexanabinol in
severe traumatic brain injury : results of a phase III randomised, placebo -controlled, clinical
trial. Lancet Neurol .5(1), 38-45.
Marmarou,
A., Lu, J., Butcher, I., et al. (2007). IMPACT database of traumatic brain injury :
design and description. J. Neurotrauma ,24(2), 239- 250.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 48of53 Amendment 3 November 15, 2011Marshall, L.F., Marshall, S.B., Klauber, M.R., et al. (1992). The diagnosis of head injury
requires a classification based on computed axial tomo graph y.J. Neurotrauma. 9 Suppl 1,
S287 -292.
Maset, A.L., Marmarou, A., Ward, J.D., Choi, S., Lutz, H.A., Brooks, D., Moulton, R.J.,
DeSalles, A., Muizelaar, J.P., Turner, H., et al. (1987). Pressure -volume index in head
injury .J. Neurosurg. 67(6), 832-840.
McCullagh,
P. (1980). Regression -models for ordinal data. J. R. Statist. Soc. Ser. B
(Methodological), 42,109–142.
McHorney , C.A., Ware, J.E., Jr, & Raczek, A.E. (1993). The MOS 36 -Item Short -Form
Health Survey (SF-36): II. Ps ychometric and c linical tests of validity in measuring ph ysical
and mental health constructs. Med. Care.,31, 247-263.
Murray , G.D., Barer, D., Choi, S., et al. (2005). Design and anal ysis of phase III trials with
ordered outcome scales: the concept of the sliding dichotomy .J. Neurotrauma., 22(5), 511-
517.
O’Brien, P.C., Fleming, T.R. (1979). A multiple testing procedure for clinical trials.
Biometrics, 35,549-556.
Pettus, E.H., Wright, D.W., Stein, D.G., and H offman, S.W. (2005). Progesterone treatment
inhibits the inflammatory agents that accompany traumatic brain injury .Brain Res., 1049,
112-9.
Roof ,R.L., Duvdevani R., and Stein, D.G. (1993). Gender influences outcome of brain
injury : Progesterone plays a protective role. Brain Res., 607, 333-336.
Roof ,R.L., Duvdevani R., Hey burn, J.W., and Stein, D.G. (1996). Progesterone rapidl y
decreases brain edema: treatment delay ed up to 24 hours is still effective. Exp. Neurol., 138,
246-251.
Roof,
R.L., Duvdevani , R., Braswell, L ., and Stein, D.G. (1994). Progesterone facilitates
cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury
in male rats. Exp. Neurol., 129, 64-69.
Roof,
R.L., Hall, E.D. (2000). Gender differences in ac ute CNS trauma and stroke:
neuroprotective effects of estrogen and progesterone. J. Neurotrauma ,17(5), 367 -388.
Roof, R.L ., Hoffman, S.W., Stein, D.G. (1997). Progesterone protects against lipid
peroxidation following traumatic brain injury in rats. Mol. Chem. Neuropathol .,31(1), 1 -
11.
Sayeed, I., Wali, B., Stein, D.G. (2007). Progesterone inhibits ischemic brain injury in a rat
model of permanent middle cerebral artery occlusion. Restor. Neurol. Neurosci., 25(2), 151-
159.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 49of53 Amendment 3 November 15, 2011Shear, D.A., Galani, R., Hoffman, S.W., and Stein, D.G. (2002). Progesterone protects
against necrotic damage and behavioral abnormalities caused b y traumatic brain injury.
Exp. Neurol., 178, 59-67.
Stein,
D.G. (2005). The case for progesterone. Ann. N. Y . Acad. Sci .,1052, 152-169.
Stein, D.G. (2008). Progesterone exerts neuroprotective effects after brain injury .Brain Res.
Rev.,
57,386-397.
Tagliaferri, F., Compagnone, C., Korsic, M., Servadei, F., & Kraus, J. (2006). A sy stematic
review of brain i njury epidemiology in Europe. Acta Neurochirurgica, 148(3), 255-268.
Teasdale, G., and Jennett, B. (1974). Assessment of coma and impaired consciousness. A
practical scale. Lancet ,2(7872), 81-84.
Teasdale, G.M., Pettigrew, L .E., Wilson, J.T., Murray , G., Jennett, B. (1998). Anal yzing
outcome of treatment of severe head injury : a review and update on advancing the use of
the Glasgow Outcome Scale. J. Neurotrauma ,15(8), 587 -597.
VanLandingham, J.W., Cekic, M., Cutler, S., Hoffman, S.W., and Stein, D.G. (2007).
Neurosteroids
reduce inflammation after TBI through CD55 induction. Neurosci Lett. ,
425(2) , 94-98.
Ware,
J.E., Jr, and Sherbourne, C.D. (1992). The MOS 36-item short- form health survey
(SF-36). I. Conceptual framework and item selection. Med. Care. 30 , 473-483.
Whitehead,
J. (1993). Sample size calculations for ordered categorical data. Statistics in
Medicine, 12, 2257- 2271.
Wilson, J.T., Pettigrew, L.E., Teasdale, G.M. (1998). Structu red interviews for the Glasgow
Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J.
Neurotrauma ,15(8) , 573-585.
Wright, D.W., Bauer, M.E., Hoffman, S.W., and Ste in, D.G. (2001). Serum progesterone
levels correlate with decreased cerebral edema after traumatic brain injury in male rats . J.
Neurotrauma, 18, 901-909.
Wright,
D.W., Kellermann, A.L ., Hertzberg, V.S., Clark, P.L ., Frankel, M., Goldstein, F.C.,
et al. ( 2007). ProTECT: A randomized clinical trial of progesterone for acute traumatic
brain injury .Ann. Emerg. Med., 49, 391-402.
Wright, D.W., Ritchie, J.C., Mullins, R.E., Kellerman, A.L., and Denson, D.D. (2005).
Steady -state serum concentrations of progeste rone following continuous intravenous
infusion in patients with acute moderate to server traumatic brain injury. J. Clin.
Pharmacol.,
45,640-648.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 50of53 Amendment 3 November 15, 2011Wu, X., Hu, J., Zhuo, L ., Fu, C., Hui, G., Wang, Y., et al. (2008). Epidemiology of
traumatic brain injury ineastern China, 2004: a prospective large case study .J. Trauma,
64(5), 1313-1319.
Xiao,
G., Wei, J., Yan W., Wang, W., and Lu, Z. (2008). Improved outcomes from the
administration of progesterone for patients with acute severe traumatic brain injury : a
randomized controlled trial. Crit. Care., 12, R61.
Xiao, G.M., Wei, J., Wu, Z.H., Wang, W.M., Jiang, Q.Z., Cheng, J., et al. (2007). Clinical
study on the therapeutic effects and mechanism of progesterone in the treatment for acute
severe head injury .Zhon ghua W ai Ke Za Zhi (Chinese Journal of Surgery), 45, 106-108.
Progesterone in Patients with Severe Traumatic Brain Injury BHR Pharm a, LLC
Page 51of53 Amendment 3 November 15, 2011APPENDIX A
SCHEDULE OF EVENTS
Study Procedure Screening
(Within 8 hrs of
injury)Day 1 -5
(infusion period:
120 hours)Day 6
(post -infusion)Days
7-15Day 30
(1 m onth)Day 90
(3 m onths)Day 180
(6 m onths)
Inclusion/exclusion criteria X
Informed consent X
Dem ographics X
Medical history X
Concomitant m edication s/procedures1X X X X
Physical exam X X
Body Weight X X
Serum /urine pregnancy test2X
Study treatment X
ECG X X
Vital Signs, pupil response3X X X
ICP3and TIL4X X X
CT scan X X
Local labs/urinalysis X X Day 15
Arterial blood gases5X X X
Daily fluid balance X X
GCS6X X X Day 15
Pre-Injury Narrative for GOS Assessment7X
GOS (in-person assessment) X X
GOS -E(in-person assessment) X X
Adverse Events X X X
Neurow orsening (if applicable) X X X
Serious A dverse Events X X X X X X
SF-36(in-person assessment) X X
Progesterone sampling8X
ICU/hospital discharge dates X X X X
Mortality X X
1To be recorded starting after informed consent has been obtained ;2Only for females of childbearing potential
3Vital Signs [heart rate (bpm), respiration rate (per min), systolic and diastolic blood pressure (mm Hg), temperature (Cº) , and pupil response ]and ICP recorded for a period of
up to 6 days; duration of ICP monitoring at discretion of the Investigator ;ICPat 4 times per day , and ICP and vital signs whenever TIL changes
4TIL recorded for up to 6 days while ICP being monitored;5ABGs daily while subject is intubated ;6GCS best score daily if possible to obtain
7Must complete within 14 days of Randomization;8To be analyzed by the Central Lab; 1blood draw on Day 2 (48+/-6hrsafter initiation of the study drug infusion);
additional PK sampling only at selected sites.
Pr o gester o ne i n P atie nts wit h Se vere Tr a u m atic Br ai n I nj ur y B H R P h ar m a, L L C 
Pa ge 5 2 of 5 3 A me n d me nt 3 N o ve m ber 1 5, 2 0 1 1 A P P E N DI X B 
L A B O R A T O R Y A S S E S S M E N T S  
( S C R E E NI N G, D A Y 6, D A Y 1 5) 
 
Ser u m C he mistr y: 
  
• As partate a mi n otra nsferase ( A S T) 
• Ala ni ne a mi n otra nsferase ( A L T) 
• Al kali ne p h os p hatase 
• Ga m ma gl uta m yl tra nsferase ( G G T) 
• S o di u m 
• P otassi u m 
• C hl ori de 
• Gl uc ose 
• T otal pr otei n 
• T otal C h olester ol 
• Tri gl yceri des 
 
 
He m at ol o g y: 
 
• W hite bl o o d cell c o u nt ( W B C) 
• Re d bl o o d cell c o u nt ( R B C) 
• He m o gl o bi n 
• He mat ocrit 
• Platelet c o u nt 
• Differe ntial W B C 
• Retic ul oc yte c o u nt 
 Uri n al ysis: 
 
• Micr osc o pic e xa mi nati o n 
• S pecific gra vit y 
• p H 
• Pr otei n 
• Gl uc ose 
• Bl o o d 
 
 
Arteri al Bl o o d G ases: 
(if t he s u bject is i nt u bate d or has a n arterial 
li ne place d; n ot re q uire d at Da y 1 5):  
 
• p H 
• Pa O 2 
• H C O 3 
• Pa C O 2 
• Sa O 2 
• Fi O 2 
 
Pr o gester o ne i n P atie nts wit h Se vere Tr a u m atic Br ai n I nj ur y B H R P h ar m a, L L C 
Pa ge 5 3 of 5 3 A me n d me nt 3 N o ve m ber 1 5, 2 0 1 1  
Ot her: 
 
• I nter nati o nal N or malize d Rati o 
(I N R) 
• Ser u m or uri ne pre g na nc y test 
(fe males of c hil d beari n g p ote ntial) – 
Scree ni n g O nl y  
 
 
 